This approach combines PDPN expression levels with radiomics data of high-grade glioma patients, incorporating the gradient boosting machine model into radiomic feature analysis and demonstrating significant correlations with both tumor heterogeneity and PDPN expression levels. Here, PDPN is linked to central nervous system cancer.